Literature DB >> 19617584

Early cognitive impairment after sedation for colonoscopy: the effect of adding midazolam and/or fentanyl to propofol.

Usha Padmanabhan1, Kate Leslie, Audrey Singyi Eer, Paul Maruff, Brendan S Silbert.   

Abstract

BACKGROUND: The sedative drug combination that produces minimal cognitive impairment and optimal operating conditions during colonoscopy has not been determined. We sought to determine if the use of propofol alone results in less cognitive impairment at discharge than the use of propofol plus midazolam and/or fentanyl in patients presenting for elective outpatient colonoscopy.
METHODS: Two hundred adult patients presenting for elective outpatient colonoscopy were randomized to receive propofol alone or propofol plus midazolam, and/or fentanyl for IV sedation. Baseline cognitive function was measured using the computerized CogState test battery (Cogstate, Melbourne, Australia) before sedation. During the procedure, sedative drug doses, depth of sedation (via the bispectral index and observer's assessment of alertness/sedation score), complications, and treatability were recorded. Patients were interviewed about recall immediately after emerging from sedation, and cognitive testing was repeated at hospital discharge. Recovery times, quality of recovery, and satisfaction with care were also recorded.
RESULTS: In the propofol plus adjuvants group, 84 patients received fentanyl 50 microg (25-100) (median [range]) and 57 patients received midazolam 2 mg (0.5-10). Patients' cognitive function at discharge was worse than their performance at baseline. However, the changes in cognitive function between discharge and baseline were not significantly different between the two groups. At discharge, 18.5% of patients were cognitively impaired to an extent equivalent to a blood-alcohol concentration of 0.05%. Sedation with propofol plus midazolam and/or fentanyl produced better operating conditions than sedation with propofol alone and was associated with shorter procedure times. Recovery times, recall, dreaming, quality of recovery, and patient satisfaction with care were similar between the groups. Administration of >2 mg of midazolam was a predictor of impaired cognitive function at discharge.
CONCLUSIONS: Significant cognitive impairment was common at discharge from elective outpatient colonoscopy. However, the addition of midazolam and/or fentanyl to propofol sedation did not result in more cognitive impairment than the use of propofol alone. Furthermore, the use of adjuvants improved the ease of colonoscopy without increasing the rate of complications or prolonging early recovery times..

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617584     DOI: 10.1213/ane.0b013e3181a6ad31

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  19 in total

1.  Nonanesthesiologist-administered propofol versus midazolam and propofol, titrated to moderate sedation, for colonoscopy: a randomized controlled trial.

Authors:  Javier Molina-Infante; Carmen Dueñas-Sadornil; Jose M Mateos-Rodriguez; Belen Perez-Gallardo; Gema Vinagre-Rodríguez; Moises Hernandez-Alonso; Miguel Fernandez-Bermejo; Ferran Gonzalez-Huix
Journal:  Dig Dis Sci       Date:  2012-05-22       Impact factor: 3.199

2.  Post-Anaesthetic Discharge Scoring System to assess patient recovery and discharge after colonoscopy.

Authors:  Lucio Trevisani; Viviana Cifalà; Giuseppe Gilli; Vincenzo Matarese; Angelo Zelante; Sergio Sartori
Journal:  World J Gastrointest Endosc       Date:  2013-10-16

Review 3.  Anaesthetic interventions for prevention of awareness during surgery.

Authors:  Anthony G Messina; Michael Wang; Marshall J Ward; Chase C Wilker; Brett B Smith; Daniel P Vezina; Nathan Leon Pace
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

4.  Independent factors affecting recovery time after sedation in patients with intellectual disabilities.

Authors:  Shigeru Maeda; Yumiko Tomayasu; Hitoshi Higuchi; Minako Ishii-Maruhama; Ayaka Yamane; Akiko Yabuki; Yuka Honda; Masahiko Egusa; Takuya Miyawaki
Journal:  Open Dent J       Date:  2015-03-31

5.  Orthodontic Protocol Using Mini-Implant for Class II Treatment in Patient with Special Needs.

Authors:  Fernando Pedrin Carvalho Ferreira; Anderson Paulo Barbosa Lima; Eliana de Cássia Molina de Paula; Ana Claudia de Castro Ferreira Conti; Danilo Pinelli Valarelli; Renata Rodrigues de Almeida-Pedrin
Journal:  Case Rep Dent       Date:  2016-10-26

6.  Assessing the safety of physician-directed nurse-administered propofol sedation in low-risk patients undergoing endoscopy and colonoscopy.

Authors:  Dharshan Sathananthan; Edward Young; Garry Nind; Biju George; Angelie Ashby; Sharon Drummond; Kasia Redel; Neville Green; Rajvinder Singh
Journal:  Endosc Int Open       Date:  2017-02

7.  The use of propofol as a sedative agent in gastrointestinal endoscopy: a meta-analysis.

Authors:  Daorong Wang; Chaowu Chen; Jie Chen; Yaxiang Xu; Lu Wang; Zhen Zhu; Denghao Deng; Juan Chen; Aihua Long; Dong Tang; Jun Liu
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

8.  Brain measures of nociception using near-infrared spectroscopy in patients undergoing routine screening colonoscopy.

Authors:  Lino Becerra; Christopher M Aasted; David A Boas; Edward George; Meryem A Yücel; Barry D Kussman; Peter Kelsey; David Borsook
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

9.  Conscious sedation procedures using intravenous midazolam for dental care in patients with different cognitive profiles: a prospective study of effectiveness and safety.

Authors:  Valérie Collado; Denise Faulks; Emmanuel Nicolas; Martine Hennequin
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Conscious Sedation and Analgesia in Colonoscopy: Ketamine/Propofol Combination has Superior Patient Satisfaction Versus Fentanyl/Propofol.

Authors:  Mohammadreza Khajavi; Azra Emami; Farhad Etezadi; Saeid Safari; Alireza Sharifi; Reza Shariat Moharari
Journal:  Anesth Pain Med       Date:  2013-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.